10:37:42 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 Ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma 2023
2023-05-05 Ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2022-09-13 10:01:00

The med-tech company PolarCool AB (publ) makes a strategic breakthrough in Finland. The company has entered into a 2-year agreement with the Finnish professional hockey club KalPa, for the use of the PolarCap® System.

PolarCool develops and markets the product PolarCap® which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, and handball, but also other sports with an increased risk of concussion.

The Finnish club KalPa plays in the Finnish top league, Liiga, and will use the PolarCap® System from the beginning of this season in an initial trial period, with the option to continue in a two-year commercial agreement after the evaluation.

KalPa's CEO Toni Saksman comments:

-As a club, we are looking forward to including the PolarCap® System in our routines around concussions. Working with and against the problems of head injuries is important to us and our players in KalPa. I hope that this is the start of a long-term collaboration with PolarCool.

PolarCool's ambition is for this to be the start of a broader establishment of the PolarCap® System in the Finnish hockey market, and the rest of the Nordic region.

PolarCool's CEO Erik Andersson comments:

-Our first agreement in Finland is very gratifying. We notice that the strengthening clinical results for the treatment are important when the clubs make decisions in Finland, not least for the medically responsible. With this agreement, the hope is that more clubs will follow KalPa and that the PolarCap® System will thus be established as a treatment method on the Finnish hockey market. In the long term, the goal is to obtain a league solution like the one in place in the SHL.

KalPa is a historic ice hockey team from Kuopio and was founded in 1929. Since 2005, KalPa has been one of the top teams in the Finnish league. KalPa is also known for producing top players, such as former NHL stars Kimmo Timonen, Olli Jokinen and Sami Kapanen.